Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Rob J who wrote (1804)	3/17/1998 6:03:00 AM
From: Tim	Respond to of 4676

I have been watching CNBC Europe this morning. Novartis released their earnings this morning (up 48% BTW), so there has been a considerable amount of discussion about the company. THERE HAS BEEN NO MENTION OF THE "DATA MANIPULATION" ISSUE. The stock is currently down less than 1% due to continued concerns over Asia. This will hopefully be a non-event for us.

To: Rob J who wrote (1804)	3/17/1998 8:23:00 AM
From: sds	Read Replies (1) \| Respond to of 4676

Why? It's called full disclosure. Isis has to tell the FDA about it, and if an investor did a FOIA (Freedom of Info. Act) search of Isis filings with the FDA, they would eventually find that. Then, everyone would be asking why Isis "covered it up". I like companies that admit to all of their problems and generally keep the good news to themselves -- those are the stocks that are ultimately big winners. This is a minor issue (hell, he wasn't even an Isis researcher), but Isis acted responsibly in issuing the press release. Imagine what an Isis short could have done with this one.... sds

To: Rob J who wrote (1804)	3/17/1998 8:47:00 AM
From: jackie	Read Replies (2) \| Respond to of 4676

To all, Company has done precisely what should be done in a situation of this nature. They have released as much information as they can, emphasizing what has not been affected by this individual's actions and commenting honestly and completely on what could have been affected. Doing otherwise would lead to serious questions about the integrity of this company. This biotech business is frustrating enough for all participants without having to deal with a liar. There is no greater sin in science than the falsification of data. The person doing this should never be allowed to practice science again. Think of the implications of how many lives could be affected. Not only from releasing a drug that is not safe when we thought it was, but even more important, lost opportunity. If researchers fail to follow leads cut off by this individual's conduct, what could be the loss in terms of time and money? History of science is filled with chance discoveries leading to vast improvements in our understanding of our world. Imagine the consequences of a liar covering over one of these discoveries for selfish gain. Discovery of penicillin is a case in point. Found by chance in a petri dish. What if the lead scientist there had crushed this discovery because of his own agenda? My compliments to the company for dealing with this issue in a straightforward, timely, and honest fashion. Regards, Jack Simmons

To: Rob J who wrote (1804)	3/17/1998 8:51:00 PM
From: carl w. trygstad	Respond to of 4676

I am a medical researcher who works in the drug development business. The FDA requires Isis to disclose any information even if it is animal specific data that shows any toxicity or change in results. They did what they had to do, in a responsible way. I do not have any inside information, other than a medical background, but have just started to accumulate Isis stock for my retirement fund. Their science is sound and the stock should go up, but it may take awhile, but I am long and patient. Carl